Brief: PegBio Enters Exclusive Commercialization Collaboration With Tenry Pharmaceutical For Paidakang In Mainland China
16/03/2026 12:54
March 16 (Reuters) - PegBio Co Ltd 2565.HK: ENTERS EXCLUSIVE COMMERCIALIZATION COLLABORATION WITH TENRY PHARMACEUTICAL FOR PAIDAKANG IN MAINLAND CHINA AGGREGATE COMMERCIALIZATION SALES TARGET OVER RMB10 BILLION, ROYALTY ABOUT HK$140 MILLION Further company coverage: 2565.HK ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Pegbio
See all newsBrief: Pegbio Enters Joint Research And Development Collaboration With SN Bioscience
Brief: Alibaba Health Inks Strategic Tie-Up With Tenry, PegBio To Launch GLP-1RA Drug
Brief: Pegbio Co Enters MoU With Rani Therapeutics
Brief: PegBio Co Posts FY Loss Attributable RMB208.4 Million
PegBio jumps most in 7 months on deal with Shanghai Tenry